Raynaud’s Newsroom

A Parent’s Story & Creative Solutions

2011-06-04T14:17:14-04:00May 17th, 2011|Stories|

After knowing for years that something was wrong but not having enough to go on to prove it, my pediatrician suspected that my then 5 year old had Juvenile Arthritis.   It took a long time to diagnose her- almost a year! Eventually she was also diagnosed with scleroderma and mixed connective tissue disease.  Her new

Comments Off on A Parent’s Story & Creative Solutions

Stepping Out to Cure Scleroderma Walk in NYC

2011-05-11T20:10:27-04:00May 11th, 2011|In The News|

The Scleroderma Foundation/Tri-State Chapter is holding an upcoming fundraising event in New York City:  Stepping Out to Cure Scleroderma Manhattan Walk Location:  Battery Park Date:  Sunday, June 12th Registration:  9:00AM          Walk: 10:15AM For further walk or volunteer information call the Scleroderma Foundation/Tri-State, Inc. Chapter office at 800-867-0885 or email sdtristate@scleroderma.org.

Comments Off on Stepping Out to Cure Scleroderma Walk in NYC

Bubble Wrap® Inspires Raynaud’s Product Idea

2011-04-23T09:12:24-04:00April 23rd, 2011|In The News|

Bubble Wrap® sponsors an annual contest that challenges students nationwide in grades six through eight to demonstrate their creativity and ingenuity by designing an invention that incorporates the use of Bubble Wrap® brand cushioning.  The children compete to win $25,000 in prizes and savings bonds. One of this year's finalists invented a way to use Bubble Wrap® to

Apricus Biosciences Files for Orphan Drug Designation for RayVa(TM)

2015-02-04T18:27:07-05:00April 14th, 2011|In The News|

Drug Intended for the Treatment of Raynaud's Phenomena, Secondary to Systemic Sclerosis   SAN DIEGO, April 13, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today its filing with the U.S. Food & Drug Administration ("FDA") requesting orphan drug designation for RayVa™, the Company's drug candidate indicated for the treatment of Raynaud's

Comments Off on Apricus Biosciences Files for Orphan Drug Designation for RayVa(TM)
Go to Top